Last reviewed · How we verify
LX22001 for Injeciton — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
LX22001 for Injeciton (LX22001 for Injeciton) — Shandong Luoxin Pharmaceutical Group Stock Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| LX22001 for Injeciton TARGET | LX22001 for Injeciton | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- LX22001 for Injeciton CI watch — RSS
- LX22001 for Injeciton CI watch — Atom
- LX22001 for Injeciton CI watch — JSON
- LX22001 for Injeciton alone — RSS
Cite this brief
Drug Landscape (2026). LX22001 for Injeciton — Competitive Intelligence Brief. https://druglandscape.com/ci/lx22001-for-injeciton. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab